The Centers for Disease Control and Prevention (CDC) is seeking to award one or more Indefinite
Delivery/Indefinite Quantity (ID/IQ) contracts for the purchase of standard commercial adult vaccines. The
establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain
vaccines at prices below those available in the commercial marketplace. These funds provide vaccines for state and
local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program
as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate
immunization by partnering with healthcare providers in the public and private sectors. The program helps assure
the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization
coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization
and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city
programs, and current and former U.S. Territories) to support adult immunization programs as provided under
Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of
vaccine for adults under any resulting contract using state and local funds.
